Estrogen plus progestin reduced risk for fracture in postmenopausal women: COMMENTARY

Papaioannou, Alexandra
May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p61
Academic Journal
The authors, using a global index, confirmed there was no net benefit of estrogen and progestin therapy even in women at high risk for fracture. However, the global index did not include such factors as the risk for dementia and the increase of gynecologic diagnostic procedures because of vaginal bleeding. The risk for probable dementia increased 2-fold in older women allocated to the estrogen and progestin therapy and probably resulted from the increase in vascular dementia. In addition, the number of women requiring diagnostic biopsies increased more than 5-fold among those allocated to combined hormones.


Related Articles

  • Estrogen plus progestin reduced risk for fracture in postmenopausal women.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p61 

    This article focuses on the role of estrogen plus progestin to reduce the risk for fracture in postmenopausal women. Analysis was by intention to treat. Fewer women in the hormone therapy group than in the placebo group had a fracture. The effect for total fracture risk remained constant across...

  • Oestrogen plus progestin doubles the risk of dementia in post-menopausal women. Sherwin Barbara B; McGill James // Evidence Based Mental Health;Nov2003, Vol. 6 Issue 4, p111 

    Examines whether estrogen plus progestin doubles the risk of dementia or mild cognitive impairment among post-menopausal women. Main outcome measures; Finding that hormone therapy increased the risk of dementia compared with placebo after a mean follow up of about four years; Conclusion that...

  • Hot Papers in the Literature.  // Journal of Women's Health (15409996);Mar2003, Vol. 12 Issue 2, p193 

    The article discusses several studies related to women health. According to a study incidence of invasive lobular carcinoma has been increasing among post-menopausal women in some parts of the U.S. Part of this may be due to changes in classification over time. However, the use of combined...

  • Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women. Guirguis-Blake, Janelle // American Family Physician;12/15/2005, Vol. 72 Issue 12, p2520 

    Presents questions and answers related to the use of hormone therapy for the prevention of chronic conditions in postmenopausal women. Advice of the U.S. Preventive Services Task Force regarding the routine use of combined estrogen and progestin for prevention of chronic conditions in...

  • Hormone Replacement Therapy in Healthy Women. Huffman, Grace Brooke // American Family Physician;12/1/2002, Vol. 66 Issue 11, p2150 

    Presents abstracts of studies on hormone replacement therapy, published on the July 17, 2002 issue of the 'Journal of the American Medical Association.' 'Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative...

  • Oestrogen plus progestin increased risk of stroke and probable dementia in postmenopausal women. Wassertheil-Smoller, S.; Hendrix, S. L.; Limacher, M.; Shumaker, S. A.; Legault, C.; Rapp, S. R.; Espeland, M. A. // Evidence Based Medicine;Nov2003, p170 

    The article focuses on a study concerning estrogen plus progestin which increased the risk of stroke and probable dementia in postmenopausal women in postmenopausal women. Respondents are 50 to 79 years old that underwent hormone replacement therapy (HRT). It mentions the Women's Health...

  • Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Meyer, H. E.; Lofthus, C. M.; Søgaard, A. J.; Falch, J. A. // Osteoporosis International;May2009, Vol. 20 Issue 5, p827 

    Fracture incidence in Oslo decreased from the 1970s to the 1990s in younger postmenopausal women, but not in older women or in men. Concurrently, hormone replacement therapy increased considerably. Using data from the Oslo Health Study, we estimated that roughly half the decline might be...

  • Drug company secretly briefed medical societies on HRT. Moynihan, Ray // BMJ: British Medical Journal (International Edition);5/31/2003, Vol. 326 Issue 7400, p1161 

    Reports that the pharmaceutical company Wyeth has admitted that it secretly briefed a number of medical societies about the results of a study into hormone replacement therapy and dementia before they were published. Way that the study shows that the company's combined estrogen and progestogen...

  • Noncardiovascular Outcomes After Hormone Therapy. Huffman, Grace Brooke // American Family Physician;12/1/2002, Vol. 66 Issue 11, p2147 

    Discusses the study 'Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up,' by S. Hulley et al, from the July 3, 2002 issue of the 'Journal of the American Medical Association.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics